Bioasis Technologies Inc.

[Available On-Demand]
Bioasis is a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.
Ticker:
BTI; BIOAF
Exchange:
TSXV; OTC
Company Type:
Company Website:
Company HQ State:
Connecticut
Company HQ Country:
United States
Year Founded:
2007
Main Therapeutic Focus:
Lead Product in Development:
xB3™-001
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Executive Chair
Bioasis Technologies, Inc.